drugset / Trial / NCT00394563

A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain

NCT00394563

Phase 2 Completed 450 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to look at the effects of RN624 on moderate to severe knee pain due to osteoarthritis. This study will look at the safety and pain relieving effects of RN624 compared to placebo over a 4 month period.

Timeline

Start
2006-03
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tanezumab Monoclonal antibody 10 ug/kg
Subject Tanezumab Monoclonal antibody 25 ug/kg
Subject Tanezumab Monoclonal antibody 50 ug/kg
Subject Tanezumab Monoclonal antibody 100 ug/kg
Subject Tanezumab Monoclonal antibody 200 ug/kg

Indications